EXXUA's commercial ramp in a crowded MDD market tests whether a differentiated 5-HT1A mechanism can achieve self-sustaining revenue before cash depletes

Aytu BioPharma is a commercial-stage biopharmaceutical company whose lead product, EXXUA, is an approved drug for major depressive disorder in adults that is now being sold to patients and doctors.

EXXUA (gepirone), a first-in-class 5-HT1A partial agonist, is FDA-approved for MDD in adults and is in early commercial launch with over 1,300 prescriptions from 450-plus unique prescribers. The thesis turns on whether EXXUA revenue grows fast enough to offset ADHD portfolio decline and reach cash-flow breakeven before the $27M cash position is exhausted. The primary risk is displacement by entrenched generic SSRIs/SNRIs and emerging differentiated entrants including Biohaven's BHV-7000 and novel mechanisms like navacaprant from Neumora.